1. CDK4/6 Inhibitors in Breast Cancer:

2. CDK4/6 Inhibitors in Breast Cancer

3. Dysregulation of the CDK4/6 Pathway

4. CDK4/6 Inhibitors in Clinical Development

5. Preclinical Data Using Palbociclib

6. Preclinical Data Using Ribociclib

7. Abemaciclib Is a Selective Inhibitor of CDK4/6

8. PALOMA-2: Study Design

9. PALOMA-2 PFS: Investigator-Assessed ITT Population

10. PALOMA-2 PFS Subgroup Analysis-ITT, Investigator Assessment

11. MONALEESA-2: Primary Endpoint Was Met Early

12. PALOMA-3: PFS

13. PALOMA-3: Postprogression Therapies

14. Consistent Clinical Benefit Seen Across PALOMA Studies

15. MONARCH 1: Disease and Patient Characteristics

16. MONARCH 1: Prior Therapies

17. MONARCH 1: Response Summary

18. MONARCH 1: Treatment Duration

19. Activity of Chemotherapy in Taxane-Treated MBC

20. MONARCH 1: Conclusions

21. MONALEESA-2: Hematological AEs

22. Palbociclib-Induced Neutropenia Is Reversible, But Chemotherapy-Induced Neutropenia Is Not

23. MONARCH 1: Most Common AEs

24. PALOMA-3: Global QoL, Functioning, and Symptoms

25. Palbociclib Approval by EMA: November 10, 2016

26. MBC: Therapy Strategies

27. Phase 2 neoMONARCH: Study Design

28. Ki67 Expression and Response at Week 2

29. neoMONARCH RECIST Response Data Over Time

30. CDK4/6 Inhibitors in Early Breast Cancer: Adjuvant Trials

31. CDK4/6 Inhibitors in Breast Cancer: Summary

32. CDK4/6 Inhibitors in Breast Cancer: Summary (cont)

33. CDK4/6 Inhibitors in Breast Cancer: Summary (cont)

34. Looking Forward

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)